Shuttle Pharmaceuticals Holdings Inc. has announced it has entered into a securities purchase agreement with a single investor for a private placement, raising approximately $2.5 million in gross proceeds. The offering, which is expected to close on or about November 4, 2025, involves the issuance of a pre-funded warrant to purchase up to 625,156 shares of common stock at an effective price of $4.00 per share, which is above the market price under Nasdaq rules. The securities have not been registered under the Securities Act of 1933 and were offered only to accredited investors. Shuttle Pharma plans to use the net proceeds for marketing, general corporate purposes, and working capital.